 SOUTH SAN FRANCISCO, Calif., June 22, 2021 GLOBE NEWSWIRE -- Satsuma Pharmaceuticals, Inc. Nasdaq: STSA, a clinical-stage biopharmaceutical company developing STS101 dihydroergotamine DHE nasal powder, a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, President and Chief Executive Officer, is scheduled to present at the SVB Leerink CNS Forum on Tuesday, June 29, 2021 at 3:40 PM Eastern Time. The conference will be held virtually with participants joining remotely on June 29th 30th. 